Meropenem-vaborbactam

Limited reviewed summaryFull monograph review pending

No original GlobalRPh dilution article is available for this record.

Reviewed product information

Applies to

Vabomere adult single-dose vial, meropenem 1 g and vaborbactam 1 g for IV infusion.

Use U.S. label section 2.3, Table 2 for bag volumes and final concentrations. The Galway examples assume a different bag preparation and final volume.

Preparation sources checked 2026-11-13.

Reconstitution

Reconstitute each vial with 20 mL of 0.9% sodium chloride injection. Gently dissolve the powder. The volume in the vial is approximately 21.3 mL.

Sources and exact locations

Claim ID: IVR-70-MEROPENEM-VABORBACTAM-001

Review basis: Separately authored institutional guidance

Source 1
VABOMERE U.S. prescribing information (opens in a new tab)
Exact location: Section 2.3, Preparation and Table 2 (SPL section 48b14b9d-edb4-4d85-baf0-06c6e604f26a)
Publisher: DailyMed / Melinta Therapeutics, LLC
Source family: U.S. product prescribing information
Retrieved: 2026-11-13T14:23:07.312855+00:00
Source 2
Galway adult IV guide: Meropenem-vaborbactam (opens in a new tab)
Exact location: Reconstitution
Publisher: Galway University Hospitals Medicines Information
Source family: Galway University Hospitals Medicines Information
Retrieved: 2026-11-13T14:23:07.512416+00:00
Separately edited hospital guidance may draw on product labeling. Only overlapping preparation steps are used.

Dilution

Use 0.9% sodium chloride injection for further dilution. Choose the bag size and vial withdrawal for the ordered dose from the U.S. preparation table.

Sources and exact locations

Claim ID: IVR-70-MEROPENEM-VABORBACTAM-002

Review basis: Separately authored institutional guidance

Source 1
VABOMERE U.S. prescribing information (opens in a new tab)
Exact location: Section 2.3, Preparation and Table 2 (SPL section 48b14b9d-edb4-4d85-baf0-06c6e604f26a); 2.4 Drug Compatibility (SPL section 14a9cb4b-df73-4f9d-b49b-1c531e424c77)
Publisher: DailyMed / Melinta Therapeutics, LLC
Source family: U.S. product prescribing information
Retrieved: 2026-11-13T14:23:07.312855+00:00
Source 2
Galway adult IV guide: Meropenem-vaborbactam (opens in a new tab)
Exact location: Infusion fluids and Methods of intravenous administration
Publisher: Galway University Hospitals Medicines Information
Source family: Galway University Hospitals Medicines Information
Retrieved: 2026-11-13T14:23:07.512416+00:00
Separately edited hospital guidance may draw on product labeling. Only overlapping preparation steps are used.

Infusion Time

Administer the diluted adult dose over 3 hours.

Sources and exact locations

Claim ID: IVR-70-MEROPENEM-VABORBACTAM-003

Review basis: Separately authored institutional guidance

Source 1
VABOMERE U.S. prescribing information (opens in a new tab)
Exact location: 2.1 Recommended Dosage (SPL section fb9778d3-3ee1-43ba-ae4d-39dff4d9c861)
Publisher: DailyMed / Melinta Therapeutics, LLC
Source family: U.S. product prescribing information
Retrieved: 2026-11-13T14:23:07.312855+00:00
Source 2
Galway adult IV guide: Meropenem-vaborbactam (opens in a new tab)
Exact location: Methods of intravenous administration
Publisher: Galway University Hospitals Medicines Information
Source family: Galway University Hospitals Medicines Information
Retrieved: 2026-11-13T14:23:07.512416+00:00
Separately edited hospital guidance may draw on product labeling. Only overlapping preparation steps are used.

Product identifiers and clinical review status

Selected prescribing information available. Full monograph review pending.

Selected product identity

Matched to U.S. product NDC 70842-120 for the preparation statements shown.

View product identifiers and primary-label provenance

Selected product scope: Vabomere adult single-dose vial, meropenem 1 g and vaborbactam 1 g for IV infusion.
Field ID: IVR-70-MEROPENEM-VABORBACTAM-META-PRODUCT_SCOPE
Primary source (opens in a new tab) | Product data elements and the claim-specific formulation described in the cited preparation sections
Complete product reconciliation: pending.
Labeler: Melinta Therapeutics, LLC
Field ID: IVR-70-MEROPENEM-VABORBACTAM-META-LABELER
Primary source (opens in a new tab) | SPL author/assignedEntity/representedOrganization/name
Complete product reconciliation: pending.
Application number(s): NDA209776
Field ID: IVR-70-MEROPENEM-VABORBACTAM-META-APPLICATION_NUMBERS
Primary source (opens in a new tab) | SPL subjectOf/approval/id/@extension
Complete product reconciliation: pending.
NDC(s): 70842-120-01; 70842-120-06
Field ID: IVR-70-MEROPENEM-VABORBACTAM-META-NDCS
Primary source (opens in a new tab) | SPL manufacturedProduct/asContent/containerPackagedProduct/code/@code and How Supplied
Complete product reconciliation: pending.
DailyMed Set ID: e237fd0f-3050-42a3-b43e-b6fb4824e93d
Field ID: IVR-70-MEROPENEM-VABORBACTAM-META-SETID
Primary source (opens in a new tab) | SPL document/setId/@root
Complete product reconciliation: pending.
SPL version: 14
Field ID: IVR-70-MEROPENEM-VABORBACTAM-META-SPL_VERSION
Primary source (opens in a new tab) | SPL document/versionNumber/@value
Complete product reconciliation: pending.
Label printed revision date: Not established
SPL effective date: 2026-02-27
Field ID: IVR-70-MEROPENEM-VABORBACTAM-META-REVISION_DATE
Primary source (opens in a new tab) | SPL document/effectiveTime/@value
Complete product reconciliation: pending.
Retrieved: 2026-11-13T14:23:07.312855+00:00
Field ID: IVR-70-MEROPENEM-VABORBACTAM-META-RETRIEVED_AT
Primary source (opens in a new tab) | Timestamp recorded when source bytes were retrieved
Complete product reconciliation: pending.
Downloaded XML SHA-256: 1228d707b3423beb564102aada6fe233febf1dcba2f5bc845d5f27bf06131fd7
Field ID: IVR-70-MEROPENEM-VABORBACTAM-META-XML_SHA256
Primary source (opens in a new tab) | SHA-256 computed over the exact downloaded XML bytes
Complete product reconciliation: pending.

What remains to be completed

Extract and verify presentation-specific IV preparation.
Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.

All medications Return to medication heading Application top